A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of a Probe CYP3A4 Inhibitor and Inducer on the Pharmacokinetics of BAY1841788 (ODM 201) in Healthy Male Volunteers

Trial Profile

A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of a Probe CYP3A4 Inhibitor and Inducer on the Pharmacokinetics of BAY1841788 (ODM 201) in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Darolutamide (Primary) ; Itraconazole; Rifampicin
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 28 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 04 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Mar 2017 Planned End Date changed from 1 Jul 2017 to 5 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top